ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SPTX vs MLTX // RSI-14 & 200D SMA MOMENTUM

Seaport Therapeutics Inc. (NASDAQ) VS. MoonLake Immunotherapeutics (Class A) (NASDAQ) • 15-METRIC TALLY: SPTX 1 — MLTX 1
▲ RSI-14 & 200D SMA MOMENTUM LEADER: MLTX
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SPTX VS. MLTX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SPTX MLTX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) — -35.00% — TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — -18.33% — TIE /fcf-yield <GO>
Operating Margin — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality — 2/9 — TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 48.5 50.0 -1.50 MLTX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.05B $1.00B $46.6M SPTX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SPTX REV MLTX REV SPTX GROSS % MLTX GROSS % SPTX FCF MLTX FCF
FY 2025 $104.6M $685.5M — — — -$196.0M
FY 2024 — $400.7M — — — -$117.1M
FY 2023 — $151.5M — — — -$42.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SPTX // BETA —
MLTX // BETA —